SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response

Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but our understanding of the requirements for a robust ICB response is incomplet...

Full description

Bibliographic Details
Main Authors: Sofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, Karlijn Hummelink, Alexandra M. Terry, Kim Monkhorst, Joyce Sanders, Ingrid Hofland, Ewout Landeloos, Yannick Van Herck, Oliver Bechter, Thomas Kuilman, Weiwei Zhong, Jean-Christophe Marine, Lodewyk Wessels, Daniel S. Peeper
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
Cancer
immunotherapy
SERPINB9
NSCLC
melanoma
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2139074

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2139074

Similar Items